Navigation Links
EpiCept Announces Reverse Stock Split and Change of Corporate Name to Immune Pharmaceuticals Inc.
Date:8/19/2013

mune licensed worldwide rights for systemic indications of bertilimumab from iCo Therapeutics in June 2011, while iCo retained rights to all ophthalmic indications. iCo originally licensed exclusive worldwide rights to bertilimumab in 2006 from MedImmune Limited (formerly known as Cambridge Antibody Technology Limited), the global biologics unit of AstraZeneca. Additionally, Immune has licensed from Yissum, the Technology Transfer Company of the Hebrew University of Jerusalem, injectable applications of the antibody nanoparticle conjugate technology (NanomAbs®) developed by Prof. Shimon Benita.  For more information, visit the Immune website at www.immunepharmaceuticals.com.

Forward-Looking Statements

This news release and any oral statements made with respect to the information contained in this news release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal" or the negative of those words or other comparable words to be uncertain and forward-looking.  Such forward-looking statements include statements that express plans, anticipation, intent, contingency, goals, targets, future development and are otherwise not statements of historical fact. These statements are based on our current expectations and are subject to risks and uncertainties that could cause actual results or developments to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results or developments to differ materially include: the risk that we may be unable to complete the propos
'/>"/>

SOURCE EpiCept Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. EpiCept Reports Second Quarter 2013 Operating and Financial Results
2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
3. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
4. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
5. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
6. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
7. WuXi PharmaTech Announces Third-Quarter 2011 Results
8. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
9. Spherix Announces Third Quarter Financial Results
10. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
11. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... (PRWEB) March 02, 2015 Shimadzu Scientific ... and present on LCMS and marijuana analysis at the ... March 8 to 12 at the Ernest N. Morial ... can stop by booth 3121 to discuss laboratory challenges ... company’s innovative, proven products help save time, money and ...
(Date:3/2/2015)... YORK and VANCOUVER, British Columbia ... Inc. ("InMed") (CSE: IN; OTCQB: IMLFF), a clinical ... cannabinoid based therapies, today announced that Craig ... company overview during a live webcast at VirtualInvestorConferences.com. ... ET LINK:   http://VirtualInvestorConferences.com > click the ...
(Date:3/2/2015)... SANTA BARBARA, Calif. , March 2, 2015 ... a biotechnology company developing therapies for autoimmune and ... Trademark Office (USPTO) has issued an important new ... immune system function through the targeting of CLIP. ... the targeted peptide technology underlying VG Life Sciences, ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 Increasing its efforts ... Films launches its first three episodes of The GMO TRUTH ... Project this month, as it continues its mission to discover ... the project's first phase, to “uncover the truth about the ... media. , The GMO Truth Podcast is an expansion of ...
Breaking Biology Technology:Shimadzu Scientific Instruments Announces Product Launches, Presentations and Poster Sessions for Pittcon 2015 2Shimadzu Scientific Instruments Announces Product Launches, Presentations and Poster Sessions for Pittcon 2015 3InMed Pharmaceuticals to Present Investor Webcast March 5 2VG Life Sciences Granted Key Composition Of Matter Patent 2VG Life Sciences Granted Key Composition Of Matter Patent 3The Walk a Mile Project Launches “GMO Truth” Podcast 2
... Inc. (NYSE: MYL ),today announced that Mylan Pharmaceuticals ... Drug Administration (FDA) for its,Abbreviated New Drug Application (ANDA) ... 200 mg., Lamotrigine Tablets are the generic version ... $1.97 billion,for the 12 months ending Sept. 30, 2007., ...
... venture syndicate invests to advance expanding pipeline of products to ... ... Fovea Pharmaceuticals SA, a,biopharmaceutical company developing novel therapeutics for the ... in a,Series B financing from a strong, international syndicate of ...
... is,GlaxoSmithKline,s (NYSE: GSK ) response to ... Evaluative Sciences (ICES) titled,"Thiazolidinediones and Cardiovascular Outcomes ... that the ICES retrospective analysis of the ... and generates misleading,conclusions regarding acute myocardial infarction ...
Cached Biology Technology:Fovea Pharmaceuticals Completes EUR30M Series B Financing 2Fovea Pharmaceuticals Completes EUR30M Series B Financing 3Fovea Pharmaceuticals Completes EUR30M Series B Financing 4GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes 2GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes 3GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes 4GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes 5
(Date:2/5/2015)... 30, 2015  It is gratifying to see that ... for genomic science as a means to better understand ... treatment.  I was honored to participate in today,s White ... program. Since the 1980s my teams ... the first sequenced genome of a free living organism, ...
(Date:1/22/2015)... MELBOURNE, Fla. , Jan. 13, 2015  Today, ... wearable technology, launched its crowdfunding campaign on Fundable, ... accelerate the build of production capacity to meet ... Photo - http://photos.prnewswire.com/prnh/20150113/168790 ...
(Date:1/22/2015)... YORK and POINT ROBERTS, Washington ... news source covering leading sectors including technology and tech stocks, ... Privacy marketplace featuring master pickpocket and security consultant Apollo ... is stolen and talks about the Wocket™ biometric smart wallet, ...
Breaking Biology News(10 mins):J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3
... are replaced through cell division. Researchers at Karolinska Institutet ... genetic information remains intact despite this continuous exchange of ... of the scientific journal Molecular Cell. , An adult ... which die and are replaced by cell division every ...
... the second major form of dementia. Under the ... Flanders Interuniversity Institute for Biotechnology (VIB) affiliated to ... the progranulin growth factor plays an important biological ... dementia. Because progranulin is known primarily for its ...
... scientists at Indiana University Bloomington report biochemical machinery ... weakest of scents. Even when ovary extracts were ... their mark. , A video demonstrating sperm chemotaxis ... can be downloaded at http://www.iuinfo.indiana.edu/bem/media_relations/movie.chemotaxis.mpg (Credit: Stephen ...
Cached Biology News:A protein complex that untangles DNA 2Researchers find cause of frontotemporal dementia 2Even when faint, ovary scent draws sperm cells 2